Status:
COMPLETED
Cardiac Fibroblast Activation Detected by 68Ga-FAPI PET/MR
Lead Sponsor:
Ruijin Hospital
Conditions:
Myocardial Remodeling After AMI
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Myocardial infarction is the most common cause of high mortality in the modern world. The short-term survival rate of ST-elevated myocardial infarction (STEMI) has been dramatically increased in the p...
Eligibility Criteria
Inclusion
- between 18-75 years old
- diagnosed with coronary angiography
- performed percutaneous coronary intervention，with successful myocardial reperfusion
Exclusion
- unstable hemodynamics
- MR contraindications (such as pacemaker or nerve stimulator or metal foreign body, high fever, severe renal failure, etc.)
- Claustrophobia
Key Trial Info
Start Date :
August 26 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 30 2022
Estimated Enrollment :
89 Patients enrolled
Trial Details
Trial ID
NCT04723953
Start Date
August 26 2020
End Date
September 30 2022
Last Update
October 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Ruijin Hospital
Shanghai, China, 200025